TY - JOUR
T1 - Lived Experience of Advanced Hybrid Closed-Loop Versus Hybrid Closed-Loop
T2 - Patient-Reported Outcomes and Perspectives
AU - Hood, Korey K.
AU - Laffel, Lori M.
AU - Danne, Thomas
AU - Nimri, Revital
AU - Weinzimer, Stuart A.
AU - Sibayan, Judy
AU - Bailey, Ryan J.
AU - Schatz, Desmond
AU - Bratina, Natasa
AU - Bello, Rachel
AU - Punel, Alina
AU - Calhoun, Peter
AU - Beck, Roy W.
AU - Bergenstal, Richard M.
AU - Phillip, Moshe
N1 - Publisher Copyright:
© Copyright 2021, Mary Ann Liebert, Inc., publishers 2021.
PY - 2021/12
Y1 - 2021/12
N2 - This article reports on the lived experience of Medtronic advanced hybrid closed-loop (AHCL) in comparison to first generation hybrid closed-loop (HCL) in a randomized, open-label, two-period crossover trial. Patient-reported outcome (PROs) measures were administered before randomization and at the end of each study period in 113 adolescents and young adults with type 1 diabetes. Glucose monitoring satisfaction subscales for emotional burden and behavioral burden improved significantly (P < 0.01) over time with use of AHCL versus HCL and co-occurred with glycemic improvements (reduced percent time above 180 mg/dL during the day and no change in % time less than 54 mg/dL across 24 h) and greater time in Auto Mode. PROs, including distress, technology attitudes, and hypoglycemia confidence, were not different. AHCL use was associated with improved glucose monitoring satisfaction. Satisfaction was greater in those participants who had more appreciable glycemic benefit and stayed in Auto Mode more often. Clinical Trial Registration number: NCT03040414.
AB - This article reports on the lived experience of Medtronic advanced hybrid closed-loop (AHCL) in comparison to first generation hybrid closed-loop (HCL) in a randomized, open-label, two-period crossover trial. Patient-reported outcome (PROs) measures were administered before randomization and at the end of each study period in 113 adolescents and young adults with type 1 diabetes. Glucose monitoring satisfaction subscales for emotional burden and behavioral burden improved significantly (P < 0.01) over time with use of AHCL versus HCL and co-occurred with glycemic improvements (reduced percent time above 180 mg/dL during the day and no change in % time less than 54 mg/dL across 24 h) and greater time in Auto Mode. PROs, including distress, technology attitudes, and hypoglycemia confidence, were not different. AHCL use was associated with improved glucose monitoring satisfaction. Satisfaction was greater in those participants who had more appreciable glycemic benefit and stayed in Auto Mode more often. Clinical Trial Registration number: NCT03040414.
KW - Adolescents
KW - Automated insulin delivery
KW - Closed loop
KW - Patient-reported outcomes
KW - Type 1 diabetes
KW - Young adults
UR - https://www.scopus.com/pages/publications/85119384790
U2 - 10.1089/dia.2021.0153
DO - 10.1089/dia.2021.0153
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 34270328
AN - SCOPUS:85119384790
SN - 1520-9156
VL - 23
SP - 857
EP - 861
JO - Diabetes Technology and Therapeutics
JF - Diabetes Technology and Therapeutics
IS - 12
ER -
